Therapeutic targets in African-American youth with type 2 diabetes

National Institute Of Diabetes And Digestive And Kidney Diseases

Investigators

Linked publications & trials

Abstract

This is a 3-month randomized trial in youth with type 2 diabetes with 2 intervention arms (metformin alone and metformin and liraglutide). Our project has successfully recruited participants but have experienced multiple delays in protocol initiation and recruitment related to interruptions in stable isotope supply at the NIH Clinical center as well as the COVID-19 pandemic. Due to the COVID-19 pandemic, recruitment was completely halted March 2020-July 2020 and restarted in August 2020. However, due to ongoing COVID-19 restrictions, we have not been able to meet have robust recruitment. Participants are being enrolled, but at slower pace. There has been another interruption in isotope supply from May 2021 till present that is affecting attainment of secondary outcomes. Our randomized study should be allowed to continue because our findings will provide novel insight into pathophysiology of diabetes in youth, the drugs used to treat this chronic disease and pharmacogenomic targets. We have published a major manuscript entitled Metformin Increases GLP-1 Concentrations and Improves Glycemia in Youth with Type 2 Diabetes of our findings and reviews in Hormone Research in Pediatrics. We have also generated pilot data for the role of microbiome in metformin treated youth and are in the process of writing a new protocol for this aim.